Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that both tofacitinib and methotrexate effectively reduced hair loss and psychological distress in patients with moderate-to-severe alopecia areata, but tofacitinib showed much greater efficacy. Both treatments had similar safety profiles, with no serious adverse effects reported.

This study compared oral tofacitinib and methotrexate in treating moderate-to-severe alopecia areata, finding that tofacitinib was more effective at reducing SALT scores and improving scalp hair assessment PRO scores, though both treatments reduced psychological distress similarly without serious adverse effects.

This study found that in an ex vivo model simulating alopecia areata, the DHODH inhibitor farudodstat reduced T-cell proliferation and MHC protein expression in hair follicles, suggesting it may protect against immune privilege collapse without cytotoxic effects.

In this six-year study of a Saudi cohort, oral tofacitinib showed favorable long-term effectiveness for patients with AA, with manageable adverse events requiring regular monitoring.

In this study, researchers assessed the effects of deferasirox in 85 children with ß-thalassemia in Kirkuk and reported that while 55.3% experienced a reduction in serum ferritin, 9.4% had adverse effects, indicating that deferasirox is generally well-tolerated as an iron chelator with modifiable side effects.

This study found that tofacitinib effectively induced hair regrowth in 62.2% of severe alopecia areata patients in Saudi Arabia after six months, with higher baseline Severity of Alopecia Tool scores and past steroid use linked to reduced response.

In this study, ritlecitinib, an oral medication approved for adolescents and adults, significantly reduced scalp hair loss and promoted eyebrow and eyelash regrowth in severe alopecia areata patients, with benefits sustained over 48 weeks and generally well-tolerated minor side effects.

This review explores current therapeutic options for frontal fibrosing alopecia, noting the use of finasteride, topical tacrolimus, hydroxychloroquine, and excimer laser in managing the condition, but reports no new clinical results.

This integrative review found that triamcinolone hexacetonide remains the primary treatment for mild to moderate alopecia areata but noted its significant side effects with prolonged use, while emerging therapies like PRP and minoxidil offer promising alternative benefits with fewer risks.

This study in Mexican adolescents with severe alopecia areata reported that oral tofacitinib treatment resulted in hair growth and reduced alopecia severity without serious adverse effects.

Teriflunomide often causes mild to moderate hair thinning and loss in MS patients, which usually improves with or without treatment.

This study found that alefacept showed no significant improvement in treating severe alopecia areata compared to placebo over a 24-week period.

The article in Dermatologic Therapy discusses clinical experiences with using tofacitinib to treat alopecia areata in 63 patients, but no specific results are reported in the abstract.

This review summarizes findings on the long-term use of tofacitinib for severe alopecia areata, reporting its potential as a promising treatment option.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

This study found that oral tofacitinib was effective and well tolerated for treating alopecia areata in most pediatric patients, with nearly 73% experiencing hair regrowth.

This study evaluated treatments for frontal fibrosing alopecia and found hydroxychloroquine and 5a-reductase inhibitors to be most effective, with 70-72% of patients experiencing stabilization or improvement, but limitations in treatment consistency and assessment methods remain.

This research reported that the FDA approved Litfulo® (ritlecitinib) as the first oral treatment for severe alopecia areata in adolescents over 12 years old, with 23% of treated patients showing significant hair regrowth in clinical trials compared to 1.6% with placebo.

In this retrospective review, tofacitinib treatment was associated with clinically significant hair regrowth in most adolescent patients with alopecia areata, though limitations suggest further studies are needed to confirm these findings.

This study found that among adults with severe alopecia areata, alopecia totalis, or alopecia universalis, oral tofacitinib was more effective than methotrexate in reducing hair loss over a 12-week period, though long-term safety and efficacy remain unestablished.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

CTP-543 is generally safe for treating alopecia areata.

This study highlights that while there are no FDA- or ANVISA-approved treatments for children with alopecia areata, JAK inhibitors are emerging as a promising therapeutic option for this population.

This study observed that oral tofacitinib was reasonably well-tolerated but had limited efficacy in treating alopecia areata, with a clinical response seen in 41.4% of patients over six months.

This study presents case reports of four patients with alopecia areata or alopecia universalis, highlighting varied responses to treatments like prednisone, intralesional triamcinolone, and squaric acid dibutyl ester.

This study found that tofacitinib was an effective and well-tolerated treatment for alopecia areata, with significant to moderate hair regrowth in 78% of patients observed.

In this study, four children with recurrent atypical teratoid rhabdoid tumors experienced disease stabilization or regression after treatment with alisertib, suggesting its potential role in future trials for this condition.

This study found that hydroxycinnamate derivatives, especially a compound named 10a, effectively inhibited SRD5A1 activity and protein expression in cell assays, suggesting potential for treating androgen-related conditions.